
Resistance to treatment for metastatic colorectal cancer (mCRC) with trifluridine–tipiracil (FTD–TPI) is associated with mutations in KRAS codon G12 (KRASG12), new research has shown. The findings demonstrate that genomic-based markers can be used to guide chemotherapy.
Like
Save
Share